Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.

Tumori - 1 Jan 2000

Fiala Ondrej, Pesek Milos, Finek Jindrich, Krakorova Gabriela, Benesova Lucie, Minarik Marek

Abstract excerpt

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pleural Effusion, Malignant

Share to Pleural Neoplasms

Share to Positron-Emission Tomography

Share to Quinazolines

Share to Retreatment

Share to Thoracic Vertebrae

Source

Identifiers

PMID: 25076254
DOI: 10.1700/1578.17234

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.PMID 25076254Read ↗

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.Semantic proximity Read ↗

Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.Semantic proximity Read ↗

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.Semantic proximity Read ↗

Trametinib Monotherapy for the Treatment of Brain Metastasis From Non-small-cell Lung Cancer: a Case ReportSemantic proximity Read ↗

Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).Semantic proximity Read ↗

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation.Semantic proximity Read ↗

Erlotinib in the first-line treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.Semantic proximity Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.Semantic proximity Read ↗

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Semantic proximity Read ↗

[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.